therapeutic antibody development

AivoCode is an emerging biotech startup developing platform technologies to improve treatment and management of neurological diseases by developing assets that promote neuroprotection and block neuroinflammation. Its technology uses an unbiased screening approach to identify molecular "zip codes" specific to diseased regions or cell types in the brain. It is developing therapeutic antibodies against an unexplored target present early in Alzheimer's disease blood vessels, and exploring therapeutic candidates in optic neuropathies including glaucoma.

neuroprotection researchunbiased screening to identify molecular zip codes

Antagen Pharmaceuticals Inc. (also named Antagen Biosciences, Inc.) is a biotechnological company providing biomedical and biotechnical services and products to the biotech/biopharmaceutical industry and biomedical community. It offers CRO/CDMO services and product development targeting infectious diseases, cancer, and autoimmune disorders, grounded in mammalian cell expression platforms, glyco-engineered CHO cell expression technology, and therapeutic antibody development.

Fut8-/- CHO cell systemgeneration of stable CHO and HEK293 cell linesglyco-engineered CHO cell expression technologyhigh-efficiency purificationIgG-IgA Technologymammalian cell expression platformsrecombinant protein production

IDBiologics was founded to discover and develop human monoclonal antibodies (mAbs) for the prevention and treatment of infectious diseases. Founded from the laboratory of Professor James Crowe at Vanderbilt University Medical Center (VUMC), its fully human mAb platform enables rapid discovery and optimization of broad and potent therapeutic mAbs with neutralizing activity to a range of viral targets. The company is based in Nashville, Tennessee.

antibody optimizationhuman monoclonal antibody discovery